TKMR — Up approximately 50%
TKMR — Up approximately 50% on news of it becoming a wholly-owned subsidiary of privately held OnCore Biopharma, and NOT for its Ebola line. At least, that”s not the stated emphasis. That contingent of shareholders may be selling on the news which has reacted down from 24.64 to 20.80. Technical analysis is less relevant at this stage, but just closing back under 22.75 would undermine potential for extending any higher while awaiting the acquisition to close.
